Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

Publisher： Karger

E-ISSN： 1423-0232|77|3-4|212-216

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.3-4, 2009-09, pp. : 212-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite

Phase I/II Study of Paclitaxel and 5-Fluorouracil as Second-Line Therapy in Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 21, Iss. 4, 1998-09 ,pp. : 305-308

Karger

Access to resources Recommend Favorite

Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 356-363

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 106-114

Karger

Access to resources Recommend Favorite